电针调控骨骼肌胰岛素受体底物-1磷酸化改善胰岛素抵抗的机制

目的:观察电针对2型糖尿病大鼠骨骼肌胰岛素受体底物-1(IRS-1)磷酸化水平的影响,从而探讨电针治疗2型糖尿病的可能机制。方法:采用2型糖尿病肥胖大鼠作为研究对象。将成模后的14只ZDF大鼠随机分为模型组、电针组,每组7只;另将7只ZL大鼠设为空白组。干预4周,检测空腹血糖(FBG),并以Western Blot法检测IRS-1酪氨酸与丝/苏氨酸磷酸化的水平,观察骨骼肌全细胞葡萄糖转运蛋白4(GLUT4)水平。结果:与模型组比较,电针组大鼠FBG、血清胰岛素(FINS)水平、胰岛素抵抗指数(HOMA-IR)均显著降低(P<0.05),且电针组可显著降低大鼠骨骼肌IRS-1丝/苏氨酸磷酸化水平,提高大鼠骨骼肌IRS-1酪氨酸磷酸化表达(P<0.05)。电针组比空白组及模型组GLUT4蛋白表达水平增高(P<0.05)。结论:电针可降低2型糖尿病ZDF大鼠FBG、FINS、HOMA-IR,同时电针可有效上调骨骼肌GLUT4蛋白表达水平,从而改善其胰岛素抵抗状况,其机制可能与电针调控骨骼肌IRS-1磷酸化水平有关。     

Nonsurgical Electrical Ablation of Tachycardias: Importance of Prior in Vitro Testing of Catheter Leads

Nonsurgical electrical ablation of tachycardia pathways or foci has been attempted or carried out using a variety of temporary pacing catheter leads. To determine the ability of such leads to withstand the high energies used in such procedures, 34 leads were suspended in saline, and subjected to repeated electrical shocks. Small (4 French) temporary pacing leads made by a variety of manufacturers tolerated multiple shocks up to 100 joules; above this level, failures became increasingly common, although usually the failure mode was benign with respect to patient care implications. Testing of 6, 7, and 8 French leads revealed considerable inter-and intra-manufacturer differences in the ability to withstand higher energy shocks, reflecting differences in materials and fabrication techniques. It is concluded that careful in vitro lead testing is required prior to using identical models in humans for arrhythmia ablation procedures.     

Decrease in bispectral index prior to cardiovascular collapse during Caesarean sections

We report a case of significant reduction in bispectral index (BIS) associated with suspected amniotic fluid embolism (AFE) that occurred prior to change in haemodynamic variables. The patient was a 29‐year‐old nulliparous, who was admitted for Caesarean section under general anaesthesia in the 33rd week of pregnancy. After the baby was born, the BIS value suddenly decreased to 0, with suppression ratio of 100. One minute later, saturation decreased abruptly to 85%, end‐tidal carbon dioxide (EtCO₂) decreased to 5 mmHg, peak inspiratory pressure increased to 35 cm H₂O, and non‐invasive blood pressure (BP) failed to obtain a reading. After administration of vasoactive drugs, the systolic BP was maintained at 100 mmHg or higher, the BIS value rose to 10–20, and the EtCO₂ increased to 24–33 mmHg. In this case, the BIS monitoring may provide an earlier warning of impending cardiovascular collapse in the case of AFE.     

Pacemaker Upgrade for Recurrent Pacemaker Syndrome Using a Redundant Contralateral Electrode in a Patient with Bilateral Venous Stenoses

Following His-bundle ablation and VVIR pacemaker implantation, severe Pacemaker syndrome developed and was treated with DDDR pacing in a 70-year-old woman. Due to bilateral subclavian vein stenosis, DDDR pacing could not be maintained and an unusual method of restoring atrioventricular synchrony is described using the contralateral redundant atrial electrode connected to the ipsilateral dual chamber pacemaker and ventricular electrode.     

Is There Any Objective Improvement of Nocturia by Combination Treatment of Zolpidem and Alpha‐Blocker Therapy for Unresponsive to Alpha‐Blocker Monotherapy in Men with Lower Urinary Tract Symptoms?

Objectives: The aim of the present study was to determine whether administration of zolpidem, a nonbenzodiazepine sedative‐hypnotic agent, at night would improve the nocturia unresponsive to alpha‐blocker monotherapy in men with lower urinary tract symptoms (LUTS). Methods: This was a prospective observational study comprised of 39 men aged 50 years and older. The study inclusion criteria were age more than 50 years, and nocturia twice or more per night after taking alpha‐blockers for more than 8 weeks. A total of 39 patients met the criteria and constituted the study cohort. Pittsburgh Sleep Quality Index (PSQI), International Prostate Symptom Score (IPSS), frequency volume chart (FVCs) and uroflowmetry were recorded. Patients were given 10 mg alfuzosin and 10 mg zolpidem once at night for the 8 weeks. Results: There were no serious side‐effects in any patient. Nocturia decreased from a baseline (3.1 ± 0.1) to 8 weeks (1.6 ± 0.2) (P = 0.001). After treatment, global PSQI scores and severe sleep disorders improved. Storage and voiding symptoms including total IPSS scores and quality of life index improved. Nocturnal urine volume and functional bladder capacity improved. Maximum flow rate, voided volume increased and residual urine volume decreased. Conclusion: Combined zolpidem and alpha‐blocker therapy resulted in a subjective and objective reduction in nocturia episodes when given to men with nocturia unresponsive to alpha‐blocker monotherapy.     

In vitro metabolism of the new insecticide flupyrazofos by rat liver microsomes

1. The in vitro metabolism of the new insecticide flupyrazofos was studied using rat liver microsomes. Two metabolites were produced and identified as O, O -diethyl O -(1- phenyl-3-trifluoromethyl-5-pyrazoyl) phosphoric acid ester (flupyrazofos oxon) and 1- phenyl-3-trifluoromethyl-5-hydroxypyrazole (PTMHP) based on UV and mass spectral analysis. 2. Cytochrome P450 oxidatively converted flupyrazofos to flupyrazofos oxon, a major metabolite and phenobarbital-induced microsomes increased this desulphuration by 8- fold. 3. Flupyrazofos oxon was converted to PTMHP with a half-life of 47 8?min by chemical hydrolysis and this conversion also proceeded non-enzymatically under our microsomal incubation conditions.     

Bilateral Decompression via Microscopic Tubular Crossing Laminotomy (MTCL) for Lumbar Spinal Stenosis: Technique and Early Surgical Result

The purpose of this study was to determine the feasibility and efficacy of bilateral decompression procedure via microscopic tubular crossing laminotomy (MTCL) for treating lumbar spinal stenosis (LSS). Seventeen patients with LSS underwent bilateral decompression via an MTCL procedure in which tubular retractor was placed. The mean age was 72 (range 59–84) years and there were 10 men and 7 women. All patients underwent pre- and postoperative dynamic lumbar x-ray, magnetic resonance (MR) image, and computed tomography. To verify the efficacy of this technique, pre- and postoperative cross-sectional area (CSA) of thecal sac, facet resection, and fatty infiltration (FI) of multifidus were measured. Clinical results were evaluated using Oswestry Disability Index (ODI), back and leg visual analog scale (VAS). The mean follow-up period was 17.5 months (range 12.1–21.2). 70.5% of MTCL was performed at the level of L4–5 and one case of dural violation (5.8%) was noted at the level of L5–S1. The mean preoperative CSA was 70.5 mm² (range 25.1–87.6) and it increased to 198.8 mm² (range 177.3–219.2) postoperatively (p = 0.00). The mean facet resection rate was 18.4% (range 9.9–26.9) and no radiological instability was noted postoperatively. MR image showed no increase in FI of the multifidus after 12 months of follow-up (p = 0.53). Preoperative clinical symptoms improved significantly at postoperative 6 months and 12 months of follow-up. These results indicate that an MTCL with use of tubular retractor system can be an effective procedure to achieve neural decompression for the treatment of LSS and it may be beneficial in preserving both facet joint and multifidus muscle.